
Rozanolixizumab improved FIQR score at 10 weeks but did not reach 2-sided statistical significance on its primary BPI-SF interference endpoint.
A key opinion leader discusses off-label treatments for fibromyalgia symptom management and promising ongoing studies, as well as mobile applications that can aid in monitoring and managing fibromyalgia symptoms.
Video content above is prompted by the following: